Sangamo Therapeutics Acquires TxCell
Richmond, California-based Sangamo Therapeutics, which is developing gene therapy, genome editing, gene regulation, and other technology, has acquired French company TxCell, Sangamo announced onMonday. Sangamo will pay approximately $84M for TxCell. TxCell is working on products related to regulatory T cell (Treg) development for immunological diseases, including Crohn's disease and multiple sclerosis.
posted on Monday, July 23, 2018
Related stories:
> Sangamo BioSciences Acquires Ceregene
> Merck Buys Sirna Therapeutics
> Iconic Therapeutics Finds $20M
> PEAR Therapeutics Gets $50M For Treating Substance Abuse With Software
> Arete Therapeutics Raises $35M
silicontap.com Home